Published in The BMJ · View the paper (DOI)
Adding tirzepatide to standard care reduces the risk of major cardiovascular events, such as heart attack or stroke, by 32% compared to sitagliptin. The study found significant benefits on individual MACE components and mortality from any cause.
Coverage from 2 institutions